NCT04377126 - Unacylated Ghrelin to Improve Functioning in PAD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

January 23, 2025

Study Completion Date

January 23, 2025

Conditions

Peripheral Artery Disease

Interventions

DRUG

Ghrelin

Ghrelin is a peptide and hormone that is primarily produced by P/D1 cells of the gastric fundus and circulates in both acylated and unacylated forms. This pilot trial will gather preliminary evidence to test investigators hypothesis that unacylated ghrelin improves walking performance and prevents mobility loss in older patients with PAD.

DRUG

Placebo

Placebo will consist of saline- no active ingredient.

Trial Locations (2)

60637

University of Chicago, Chicago

60611-3008

Northwestern University Feinberg School of Medicine, Chicago

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

Northwestern University

OTHER